Servier have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.
The collaboration covers the worldwide co-development of BCL-2 selective inhibitor candidates that are now entering into clinical development.
Proteins of the BCL-2 family are crucial regulators of apoptosis.
Deregulations of this protein family play a major role in the aberrant survival of tumor cells.
Servier will remain responsible for research activities and will share responsibilities with Novartis to conduct a clinical development program aimed at moving swiftly to a first indication for the benefit of patients.
Commercialization rights to products arising from the collaboration will be allocated between the parties on a geographic basis.
For further deal information visit Current Agreements (subscription required)
Read: Novartis Company Profile
Report: Partnering Deals and Alliances with Novartis
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity